Press Release

25 Sep, 2018 - Mississauga, ON, Canada (September 25, 2018) – Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. (“Therapure”) and an innovative developer of plasma-derived therapeutics, today provided an update on continued progress in its Phase III multicenter clinical trial of PlasmaCap™ IG (Intravenous Immunoglobulin or “IVIG”), an investigational IVIG replacement therapy being studied in both adult and pediatric patients with primary immune deficiency diseases (“PIDD”).  The study received approval to proceed from the U.S. Food and Drug Administration (“FDA”) and Health Canada in summer 2017. PlasmaCap IG has been developed utilizing Evolve’s innovative PlasmaCap EBA™ technology, which allows for more efficient capture of plasma proteins and offers the potential of higher yields and purities, compared to traditional manufacturing processes used in…

Press Release

04 May, 2018 - Mississauga, ON, Canada (May 4, 2018) – Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. (“Therapure”) and an innovative developer of plasma-derived therapeutics, today announced that it has dosed the first pediatric patient in its Phase III multicenter clinical trial of PlasmaCap™ IG (Intravenous Immunoglobulin or “IVIG”), in addition to having administered half of the infusions required for the adult portion of the study, which completed enrollment in February 2018. The study received approval to proceed from the U.S. Food and Drug Administration (“FDA”) and Health Canada last summer.  PlasmaCap IG is an investigational IVIG replacement therapy being studied in both adult and pediatric patients with primary immune deficiency diseases (“PIDD”). PlasmaCap IG has been developed utilizing Evolve’s innovative PlasmaCap EBA™ technology, which…

Press Release

28 Mar, 2018 - Mississauga, ON, Canada – March 28, 2018 – Evolve Biologics, the biologics division of Therapure Biopharma Inc., today announced that in February 2018 the company confidentially submitted a draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common shares. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions. 

Press Release

23 Mar, 2018 - Mississauga, ON, Canada (March 23, 2018) – Therapure Biopharma Inc. (“Therapure”) today announced it has launched its plasma products and technology division as Evolve Biologics (“Evolve”), an innovative developer of plasma-derived therapeutics, led by an experienced senior management team.  Evolve’s leadership team consists of Chief Executive Officer Blaine Forshage; Chief Commercial Officer, David Holliday; and Chief Financial Officer, Gregory Gould. All three industry veterans bring significant experience in the global plasma-derived therapeutics market.